What is ARA-290 and how does it work?

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B surface of erythropoietin. It selectively activates the Innate Repair Receptor (EPOR/CD131), triggering tissue protection and nerve repair pathways without stimulating red blood cell production.

Can ARA-290 actually regenerate nerves?

Phase II trial data from sarcoidosis patients showed a 23% increase in corneal nerve fiber area with 4 mg daily dosing, confirmed by the nerve growth marker GAP-43. This represents structural regeneration, not just pain reduction.

Does ARA-290 thicken the blood like EPO?

No. ARA-290 was specifically engineered to be incompatible with the hematopoietic EPO receptor. Clinical trials confirmed that hematocrit, hemoglobin, and platelet counts remain stable during treatment.

What are the side effects of ARA-290?

In clinical trials, ARA-290 showed mild injection site reactions in fewer than 5% of patients, nausea in fewer than 3%, and headache or fatigue in fewer than 2%. No serious adverse events were reported, though long-term safety data beyond 28 days does not exist.

Is ARA-290 available for prescription?

No. Araim Pharmaceuticals closed operations and no active IND applications exist. The molecule received orphan drug status but was never submitted for final FDA approval. No pharmaceutical-grade source currently exists.

Is ARA-290 banned in sports?

Yes. As an EPO-derived peptide, ARA-290 falls under WADA category S0 (non-approved substances). Any use is strictly prohibited for athletes subject to anti-doping rules.

What is the half-life of ARA-290?

ARA-290 has a very short half-life of approximately 20 minutes via subcutaneous injection. Despite this, its metabolic effects (HbA1c and lipid improvements) persisted for 28 days beyond the final dose in diabetic trials.

What biomarkers should be tracked with ARA-290?

Key biomarkers include hs-CRP (systemic inflammation), HbA1c (metabolic health), and the inflammatory cytokines TNF-alpha and IL-6, which are direct targets of the IRR-mediated anti-inflammatory cascade.

ARA-290 Peptide Profile: Nerve Repair Research

ARA-290 was engineered to solve one of the oldest problems in tissue-protective medicine: how to use erythropoietin's repair signaling without triggering dangerous blood thickening.

Scientists Michael Brines and Anthony Cerami identified that EPO has a dual identity. Beyond its well-known role in red blood cell production, it functions as a master protector of stressed tissue. The problem is that using native EPO for tissue repair requires supraphysiological doses that send hematocrit levels dangerously high, creating a concentration of red blood cells that invites life-threatening clots.

ARA-290 solved this by isolating the helix-B surface of the EPO molecule. This 11-amino-acid sequence maintains the tissue-protective signal while remaining spatially incompatible with the receptor responsible for blood production.

The result is a molecule that activates the body's innate repair systems with precision, offering tissue protection without the cardiovascular risks that made therapeutic EPO use so dangerous.

ARA-290's specificity comes from its target: the Innate Repair Receptor (IRR), a heterodimeric complex of the erythropoietin receptor (EPOR) and the beta-common receptor (CD131).

The IRR functions like an emergency response system. It is barely present in healthy tissue but is rapidly upregulated the moment a cell experiences injury, metabolic stress, or inflammatory damage.

Once ARA-290 binds to the IRR, it triggers the JAK2 pathway, recruiting survival cascades including PI3K/Akt and ERK1/2. This activation suppresses the NF-kB pathway, halting the production of pro-inflammatory cytokines (TNF-alpha, IL-6) before they can amplify tissue damage.

This is what separates ARA-290 from conventional anti-inflammatory drugs: it reprograms the cellular stress response at the signaling level rather than blocking a single downstream molecule.

The strongest human evidence for ARA-290 comes from Leiden University Medical Center, where researchers used the cornea as a transparent window to visualise nerve architecture in real time.

The cornea is the most densely innervated tissue in the human body. In Phase II trials of sarcoidosis patients with small fiber neuropathy, ARA-290 produced measurable structural regrowth:

Structural regrowth: Patients receiving 4 mg daily showed a 23% increase in Corneal Nerve Fiber Area (CNFA)
Statistical significance: Placebo-corrected mean increase of 697 micrometers squared per mm squared (p = 0.012)
Active regeneration marker: Biopsies showed increased GAP-43, a growth cone protein that proves nerves are actively rebuilding

This is the critical distinction: ARA-290 did not just reduce pain scores. It physically reconstructed the nerve bed, a structural endpoint that standard neuropathic pain medications (gabapentin, pregabalin, duloxetine) do not achieve.

During Phase II trials in Type 2 Diabetes patients, ARA-290 produced metabolic improvements that outlasted the treatment window by weeks.

HbA1c durability: A -0.21% reduction that persisted to Day 56, a full 28 days after the final dose
Triglyceride improvement: From a baseline of 2.35 mmol/L, significant movement toward healthy ranges (p = 0.043)
Cholesterol ratio: Improved cholesterol-to-HDL ratios (p = 0.039)

The persistence of these effects beyond the dosing period is significant. ARA-290 has a half-life of approximately 20 minutes, meaning the metabolic improvements cannot be explained by residual drug activity. The likely explanation is that IRR activation preserves pancreatic islet function and reduces systemic insulin resistance, producing effects that continue after the peptide itself has cleared.

The IRR is expressed across nearly every organ system, and preclinical research has identified several high-impact applications beyond nerve repair:

Kidney Protection

ARA-290 acts as a chemo-protective agent in cisplatin-induced nephrotoxicity models, shielding the kidneys from DNA damage and oxidative stress caused by aggressive cancer treatments. In transplant models, flushing donor kidneys with ARA-290 improved renal function post-reperfusion and reduced long-term interstitial fibrosis.

Cerebral Ischemic Stroke

In mouse models (Wang et al., 2024), ARA-290 significantly decreased brain infarction volume and improved neurological recovery scores after stroke.

Diabetic Wound Healing

The peptide accelerates chronic wound closure by increasing angiogenesis (new blood vessel growth) and suppressing local inflammatory cascades.

All of these applications remain entirely preclinical. No human data exists for any organ-protective indication beyond neuropathy and metabolic effects.

As of April 2026, ARA-290 is effectively a ghost molecule in the regulatory system.

Developer closed: Araim Pharmaceuticals, the primary developer, has shut down operations
No Phase III trials: Despite positive Phase II data, no large-scale confirmatory trials were ever initiated
Orphan drug status: The molecule received orphan designation but was never submitted for final FDA approval
Cause of stalling: Commercial and organisational factors, not safety failures

There is currently no legal, pharmaceutical-grade source of ARA-290 in the United States. The 'research only' versions found through online vendors carry risks of contamination, incorrect amino-acid sequences, and degraded material due to inadequate cold-chain logistics.

For athletes, the status is even more restrictive: the World Anti-Doping Agency classifies EPO-derived peptides under S0 (non-approved substances), making any use strictly prohibited in competition.

ARA-290 represents a shift from symptom management to disease modification in neuropathic medicine. The Phase II nerve regeneration data is the strongest evidence in the pipeline, with structural endpoints that go beyond pain reduction. However, the complete absence of Phase III trials and the closure of Araim Pharmaceuticals leave significant gaps in both efficacy confirmation and long-term safety. The preclinical organ-protective data spans kidney, brain, and cardiovascular systems, but none has been confirmed in humans. Until another organisation advances the molecule through large-scale trials, ARA-290 remains a proof-of-concept for IRR-mediated tissue repair, not a clinical therapy.

PEPTIDE: ARA-290

1.The Erythropoietic Paradox: Repair Without the Risk

2.The Innate Repair Receptor: An Injury-Activated Target

Explore This Protocol

Safety Triggers

Research Gaps

Contrarian Views

Protocol Reference

Related Research

Inflammation Reduction

ARA-290 Supplements

KPV (Lysine-Proline-Valine)

Muscle Growth: Hypertrophy

Fat Loss: Lipolysis

Injury Repair: Tendons / Ligaments

Stay Ahead of the Research

3.Nerve Regeneration: The Clinical Evidence

4.The Metabolic Signal: Glucose and Lipid Stabilisation

5.Preclinical Frontiers: Beyond Neuropathy